Please assess the completion status of the following clinical trial:

Trial Title: First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced Stage IIIB not amenable to local therapy or Stage IV (metastatic) NSCLC with adenocarcinoma histology.~* Never smokers or light ex-smokers.(ceased smoking at least 15 years before Day 1 of study treatment and 10 pack-years or fewer)~Exclusion Criteria:~* Had prior chemotherapy, biological (including targeted therapies such as EGFR and vascular epidermal growth factor (VEGF) inhibitors) or immunological therapy.~* Pre-existing idiopathic pulmonary fibrosis evidence by CT scan at baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): gefitinib
- 2 (Type: ACTIVE_COMPARATOR): Carboplatin/Paclitaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).